Loracarbef (LY163892) versus cefaclor in the treatment of bacterial skin and skin-structure infections in an adult population.

[1]  R S Woodward,et al.  The effect of prescribed daily dose frequency on patient medication compliance. , 1990, Archives of internal medicine.

[2]  R. F. Brown,et al.  Comparative reactivity of 1-carba-1-dethiacephalosporins with cephalosporins. , 1990, Journal of medicinal chemistry.

[3]  E. C. Wu,et al.  3-Sulfonyl-1-carba-1-dethiacephems , 1989 .

[4]  J. Washington,et al.  In vitro activities of LY163892, cefaclor, and cefuroxime , 1988, Antimicrobial Agents and Chemotherapy.

[5]  R. Baltimore.  Treatment of impetigo: a review , 1985, Pediatric infectious disease.

[6]  M. Tanner,et al.  The nature of an infectious disease practice in a community hospital. , 1983, Reviews of infectious diseases.

[7]  H. Moffet.  Common infections in ambulatory patients. , 1978, Annals of internal medicine.